Here are the S-3 shelf registrations from Editas Medicine, Inc. (EDIT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow EDIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDIT filings page.
Editas Medicine, Inc. (EDIT) has filed a shelf registration statement that permits the company to offer and sell up to $400,000,000 of securities, including common stock, preferred stock, debt securities, depositary shares, subscription rights, purchase contracts, warrants and units, from time to time after effectiveness.
Within this shelf, Editas has also filed a sales agreement prospectus for an at-the-market (“ATM”) program covering up to $150,000,000 of common stock to be sold through Leerink Partners LLC; these ATM shares are included in the $400,000,000 overall capacity. The company’s common stock trades on the Nasdaq Global Select Market under the symbol EDIT.
Net proceeds from any offerings may be used for general corporate purposes, including research and development, potential acquisitions, debt repayment or refinancing, working capital and capital expenditures. As of July 31, 2026, Editas had 153,580,035 shares of common stock outstanding out of 390,000,000 authorized, plus 5,000,000 authorized shares of preferred stock with none outstanding.